Cytel News

Cytel Inc., an advanced 

Global COVID-19 Clinical Trial Tracker

Cytel Inc. has launched an open-access global COVID-19 Clinical Trial Tracker to help facilitate greater collaboration between researchers, policymakers, clinicians, journalists, philanthropists, and other critical stakeholders who need to understand the complex dynamics of the global response to finding a solution to the COVID-19 outbreak.

Collaboration to accelerate new clinical trial technologies and techniques for disease-focused RWE production

Clinical trial biostatistics and advanced data analytics leader Cytel Inc. joined the Massachusetts Institute of Technology Center for Biomedical Innovation’s New Drug Development Paradigms (NEWDIGS) initiative as a strategic partner.

Waltham MA, March 04, 2020 — A new paper authored by statistical experts at Cytel has been published in the world-renowned journal CA: A Cancer Journal for Clinicians. The open-access paper, titled ‘An Overview of Precision Oncology Basket and Umbrella Trials for Clinicians,’ provides a valuable resource for increasing master protocol trial literacy among the many clinicians and researchers who may not be familiar with these innovative trial types. Such trials offer considerable potential value in more rapidly bringing new oncology therapeutics to patients. However, there is a critical need for improved understanding in order to optimize their use. To further address this need, Jay Park, Director at Cytel and lead author on the article, will host a free 60-minute webinar on March 19, to expand on the contents of the article, discussing the unique features of umbrella and basket trials and outlining the key considerations for their successful design and implementation.

Copenhagen, Denmark —ISPOR Europe 2019 —November 05 2019—Cytel Inc. (“Cytel” or the “Company”), the leading provider of innovative analytical software and consulting services to the biopharmaceutical sector, and a portfolio company of New Mountain Capital, today announced that it has acquired MTEK Sciences (“MTEK”) to further expand its advanced real-world analytics (RWA) capabilities.

Cytel Inc., the leading global provider of innovative analytical software and consulting services to the life sciences industry, has announced that the Complex Innovative Trial Design Symposium and East® Training will take place November 6–7 at Alexion’s headquarters in Boston, Massachusetts. The event will bring together industry-leading experts to discuss innovative solutions to pressing challenges including rare disease clinical trials.

Cytel Inc., the leading global provider of analytical solutions to the life sciences industry, today announced that it will launch East On Demand™ at the annual Joint Statistical Meetings (JSM) 2019 (July 27 – August 1, Denver, Colorado). Offered via the cloud and licensed through subscriptions, East On Demand provides statisticians with more flexible access to East, the industry standard software package for the effective design of adaptive and innovative clinical trials.

Cytel Inc., the leading global provider of innovative analytical software and services to the life sciences industry, and Axio Research, a premier provider of biostatistics to pharmaceutical, biotechnology and medical device companies, today announced that they have joined forces to create the largest global biometrics organization focused on delivering advanced analytical solutions for the life sciences industry. The merged business will operate under the Cytel brand, with Axio continuing to provide its renowned data monitoring committee services for clinical trials, as “Axio, a Cytel company.”

Cytel announced the appointment of Joshua Schultz as Chief Executive Officer (CEO) effective January 7th, 2019. He succeeds Joseph Avellone, who acted as Cytel’s interim CEO from March 2018 and will continue to serve on the company’s Board of Directors.

Mr. Schultz is an accomplished leader with a 20-year track record of success in life sciences and clinical research organizations. He joins Cytel from PAREXEL, where he most recently served as an Officer of the company and Senior Vice President for its Access business unit.